0.6900SEK+1.47%Mkt Cap: 229.15M SEKP/E: —Last update: 2026-05-13
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in …
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-14.30
PEG—
P/B1.86
P/S—
EV/EBITDA-1.35
EV/Revenue—
EPS (TTM)-0.25
EPS (Forward)-0.05
Cash Flow & Leverage
FCF Yield-14.52%
FCF Margin—
Operating CF-51.94M SEK
CapEx (TTM)—
Net Debt/EBITDA2.32
Net Debt-126.99M SEK
Technical
SMA 500.6776 (+1.8%)
SMA 2000.7215 (-4.4%)
Beta0.92
S&P 52W Chg24.23%
Avg Vol (30d)874.19K
Avg Vol (10d)665.55K
Technical Indicators
RSI (14)51.9
MACD0.0016
MACD Signal0.0024
MACD Hist.-0.0007
BB Upper0.7304 SEK
BB Middle0.6931 SEK
BB Lower0.6557 SEK
BB Width10.77%
ATR (14)0.0488 SEK
Vol Ratio (20d)0.67x
52W Range
0.551510% of range1.958
52W High1.958 SEK
52W Low0.5515 SEK
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE-50.22%
ROA-41.86%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity—
Current Ratio6.19
Quick Ratio6.18
Book Value/Sh0.3840 SEK
Cash/Share0.4520 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.320.49M
Float200.11M
Insiders20.28%
Institutions12.98%
Analyst Consensus
Rating—
Target (Mean)3.600 SEK
Target Range1.900 SEK – 5.300 SEK
# Analysts2
Company
Market Cap229.15M SEK
Enterprise Value74.00M SEK
Revenue (TTM)—
Gross Profit-40.16M SEK
Net Income (TTM)-54.17M SEK
Revenue/Share—
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees6
Last Price0.6900 SEK
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009581051